Diagnostyka (FRA:7JS) Total Stockholders Equity: €138.3 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7JS Diagnostyka SA FRA:7JS
18 GF Score
Price €39.36
! 1 Warning Sign
View Full Analysis

What is Diagnostyka Total Stockholders Equity?

Diagnostyka FRA:7JS +2.13% 18 Total Stockholders Equity is €138.3 Mil as of Mar. 2026. GuruFocus rates FRA:7JS with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Diagnostyka's Total Stockholders Equity for the quarter that ended in Mar. 2026 was €138.3 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Diagnostyka's Book Value per Share for the quarter that ended in Mar. 2026 was €4.10. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Diagnostyka's Debt-to-Equity for the quarter that ended in Mar. 2026 was 1.83.


Diagnostyka  (FRA:7JS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Diagnostyka's Book Value per Share for the quarter that ended in Mar. 2026 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Diagnostyka's Debt-to-Equity for the quarter that ended in Mar. 2026 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diagnostyka Total Stockholders Equity Related Terms


Diagnostyka Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Diagnostyka's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnostyka Total Stockholders Equity Chart

Diagnostyka Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
100.09 71.49 74.37 95.76 120.86

Diagnostyka Quarterly Data
Dec21 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 112.60 96.29 113.26 120.86 138.28
FRA:7JS
18GF Score
Diagnostyka SA FRA:7JS
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of €138.3 Mil mean?
Diagnostyka (FRA:7JS) has a Total Stockholders Equity of €138.3 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Diagnostyka and its competitors.
Is Diagnostyka's Total Stockholders Equity too high?
Diagnostyka's current Total Stockholders Equity is €138.3 Mil. Overall, Diagnostyka has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Diagnostyka's Total Stockholders Equity compare to TMO and DHR?
Diagnostyka's Total Stockholders Equity of €138.3 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Diagnostics & Research company?
A good Total Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Diagnostyka and its competitors. Diagnostyka's current Total Stockholders Equity is €138.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostyka stock overvalued right now?
Diagnostyka (FRA:7JS) has a current Total Stockholders Equity of €138.3 Mil. The current Total Stockholders Equity is €138.3 Mil. Diagnostyka's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Diagnostyka (FRA:7JS), the current Total Stockholders Equity is €138.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diagnostyka Business Description

Other Exchanges DIA:Poland
Address Ul. Prof. Michala Zyczkowskiego 16, Krakow, POL, 31-864
Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.
18GF Score

Get the complete analysis for FRA:7JS

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€39.36
Price